Clinical trials
Liver Cirrhosis, Alcoholic clinical trials
Below are recruiting liver cirrhosis, alcoholic clinical trials, each written for real people, not researchers. We’re tracking 91 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT07471542Recruiting
Copper supplements for cirrhosis patients
This trial tests whether taking copper supplements can help people with cirrhosis (scarring of the liver) who have low copper levels or symptoms related to copper deficiency. It aims to see if this can improve their health.
Seattle, WashingtonAges 18 years+ - NCT06526104RecruitingPhase 2
Tremelimumab and durvalumab for advanced liver cancer with Child-Pugh B
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
San Antonio, TexasAges 18 years+ - NCT05726032RecruitingPhase 2
Empagliflozin for fluid buildup from cirrhosis
This Phase 2 study tests empagliflozin to see if it can improve fluid buildup (ascites) in people with cirrhosis. It may help reduce symptoms related to fluid retention, but you must meet specific safety and stability requirements.
New Haven, ConnecticutAges 18 years+ - NCT06152250Recruiting
Fatty liver inflammation study with liver biopsy
This study looks at how the liver's immune environment changes in people with non-alcoholic fatty liver disease (NAFLD) that has progressed to significant scarring. Researchers will use a liver biopsy to understand the inflammation better, which may lead to new treatments.
Lyon, Auvergne-Rhône-AlpesAges 18 years+ - NCT05332613Recruiting
Diet and meal timing study for fatty liver
This study looks at whether changing when and how people eat can improve fatty liver disease caused by metabolic problems. It uses MRI to measure liver fat and compares outcomes while participants follow a structured eating schedule.
New York, New YorkAges 18–65 - NCT03635541Recruiting
Liver health changes in fatty liver disease
This study tracks how liver scarring (fibrosis) and fat buildup (steatosis) change over time in people with nonalcoholic fatty liver disease (NAFLD). It helps doctors understand risk factors so they can better predict and manage the disease.
Beijing, Beijing MunicipalityAges 18–70 - NCT04371042Recruiting
Study of liver disease and genes in people with fatty liver
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Roma, Rome/lazio/italyAges 18 years+ - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06519448Enrolling by invitation
Testing a pill for non-alcoholic fatty liver disease
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
PragueAges 18–75 - NCT07270601Recruiting
Ultrasound test for liver fat
This study is testing a new ultrasound method to measure fat in the liver. It is for people who may have a liver condition or have risk factors like diabetes or obesity, as well as healthy volunteers.
Seattle, WashingtonAges 18–75 - NCT03151473Recruiting
Study of adults with fatty liver and NASH over time
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
Hong KongAges 18 years+ - NCT07160946Recruiting
Liver cancer risk check for people with hepatitis B
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
Guangzhou, GuangdongAges 30–75 - NCT04357600Enrolling by invitationPhase 1/Phase 2
Stem cell treatment for hepatitis B–related cirrhosis
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
Jakarta, DKI JakartaAges 18–65 - NCT06661655Recruiting
Testing a new ultrasound for liver fat in MASLD patients
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
AngersAges 18–80 - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75 - NCT05178069RecruitingPhase 2
Probiotic supplement study for alcohol use disorder and liver injury
This Phase 2 trial studies whether a probiotic (LGG) can improve health in people with alcohol use disorder and alcohol-related liver injury. It’s not an alcohol treatment study, so participants are mainly joining to see how the supplement affects the body and liver-related outcomes.
Louisville, KentuckyAges 21–65 - NCT07452744Enrolling by invitation
Picroliv for non-alcoholic fatty liver disease
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Chandigarh, ChandigarhAges 18–60 - NCT06338215Recruiting
Moderate drinking vs. abstention advice for adults
This study compares two approaches for adults who drink regularly: advice on drinking in moderation vs. advice to stop drinking entirely. The goal is to see which approach better prevents major diseases and early death over time.
Pamplona, NavarreAges 50–75 - NCT05433948Enrolling by invitation
Testing ways to diagnose mild brain changes in liver disease
This study looks at how well simple brain tests can detect early (minimal) thinking changes related to liver cirrhosis. It may help doctors spot these changes sooner and diagnose the condition more accurately.
EsbjergAges 18–90 - NCT03224949Recruiting
Study comparing fatty liver types and healthy livers
This study compares liver samples and blood tests from people with alcohol-related fatty liver disease, alcohol-related hepatitis, and cirrhosis (including some with liver cancer) against healthy controls. It aims to better tell these liver conditions apart and understand what is different between them.
Cleveland, OhioAges 18–75 - NCT07610837RecruitingPhase 2
Testing AZD2389 for fatty liver disease with scarring
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
Chandler, ArizonaAges 18 years+ - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75
Hear when a new Liver Cirrhosis, Alcoholic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cirrhosis, alcoholic?
- Yes. Clin2 currently lists 91 recruiting liver cirrhosis, alcoholic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cirrhosis, alcoholic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cirrhosis, alcoholic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.